EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A multicenter performance evaluation of imipenem-relebactam gradient diffusion susceptibility testing for Pseudomonas aeruginosa

Rhiannon V Macom iD, Edith Csiki-Fejer iD, Aurelie Collange, Dwight J Hardy, Mandy Wootton iD, Gilles Zambardi, Melanie L Yarbrough iD

Microbiology Spectrum · 09.11.2026

DOI: 10.1128/spectrum.02172-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, online erschienen am 09.11.2026. Verfasst von Rhiannon V Macom und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imipenem-relebactam (I/R) is a beta-lactam/beta-lactamase inhibitor combination given with cilastatin that is indicated for the treatment of complicated urinary tract infections, including pyelonephritis and complicated intra-abdominal infections in patients. Recently, a new gradient diffusion method for antimicrobial susceptibility testing of this antibiotic was developed for Pseudomonas aeruginosa (ETEST IRPA) as an alternative to broth microdilution (BMD). Our objective was to evaluate the performance of the I/R ETEST in comparison to BMD across three external and one internal study sites for 437 (77 challenge, 360 clinical) P. aeruginosa isolates. Using the U.S. Food and Drug Administration (FDA) interpretive breakpoints, ETEST IRPA achieved a 97.7% (427/437) essential agreement (EA), 91.1% (398/437) categorical agreement (CA), 0% very major errors (VMEs), 0.9% (3/329) major errors (MEs), and 8.2% (36/437) minor errors (mEs). Using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive breakpoints, ETEST IRPA achieved a 97.7% (427/437) EA, 93.8% (410/437) CA, 12% (13/108) VME, and 4.2% (14/329) ME. Both bias and trending were in alignment with regulatory requirements. Reproducibility testing on 10 strains showed 99.6% (269/270) of results were within ±1 doubling dilution of the modal minimum inhibitory concentration (MIC). MIC 50 and MIC 90 values for imipenem were 8 and 32, respectively, in comparison to 1 and 8 with the addition of relebactam as determined by ETEST. In conclusion, ETEST IRPA provides both accurate and reproducible results for performing antimicrobial susceptibility testing of P. aeruginosa when interpreted with both FDA and EUCAST criteria. IMPORTANCE Antimicrobial susceptibility testing is key to proper treatment of bacterial infections. Broth microdilution is the gold standard for antimicrobial susceptibility testing; however, it can be time-consuming and requires high levels of technical expertise. This study evaluates a new gradient diffusion method for antimicrobial susceptibility testing of imipenem-relebactam against Pseudomonas aeruginosa . The findings support the use of imipenem-relebactam gradient diffusion as an accurate and reproducible method of antimicrobial susceptibility testing against Pseudomonas aeruginosa .

Schlagwörter

Stichwörter der Autor:innen

ETESTPseudomonas aeruginosagradient diffusionimipenem-relebactam

Autor:innen und Institutionen

  • Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • bioMérieux Clinical Affairs, Saint Louis, Missouri, USA.
  • bioMérieux Clinical Affairs, Marcy-l'Etoile, France.
  • Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.
  • Specialist Antimicrobial Chemotherapy Unit, Public Health Wales Microbiology, University Hospital of Wales, Cardiff, United Kingdom.

ORCID-Profile: Rhiannon V Macom, Edith Csiki-Fejer, Mandy Wootton, Melanie L Yarbrough

Zitieren

APA

Macom, R. V., Csiki-Fejer, E., Collange, A., Hardy, D. J., Wootton, M., Zambardi, G., & Yarbrough, M. L. (2026). A multicenter performance evaluation of imipenem-relebactam gradient diffusion susceptibility testing for Pseudomonas aeruginosa. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02172-26

Vancouver

Macom RV, Csiki-Fejer E, Collange A, Hardy DJ, Wootton M, Zambardi G, et al. A multicenter performance evaluation of imipenem-relebactam gradient diffusion susceptibility testing for Pseudomonas aeruginosa. Microbiology Spectrum. 2026. doi:10.1128/spectrum.02172-26

BibTeX
@article{Macom2026,
  author = {Macom, Rhiannon V and Csiki-Fejer, Edith and Collange, Aurelie and Hardy, Dwight J and Wootton, Mandy and Zambardi, Gilles and Yarbrough, Melanie L},
  title = {A multicenter performance evaluation of imipenem-relebactam gradient diffusion susceptibility testing for Pseudomonas aeruginosa},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.02172-26}
}
Kostenlos starten →